GILEAD SCIENCES SL
- Country
- 🇪🇸Spain
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- $95.8B
Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-04-21
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT03060447
- Locations
- 🇺🇸
Peter Shalit, MD, Seattle, Washington, United States
🇺🇸Central Texas Clinical Research, Austin, Texas, United States
🇺🇸Zuckerberg San Francisco General, San Francisco, California, United States
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
- Conditions
- Interventions
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2020-05-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 883
- Registration Number
- NCT03053063
- Locations
- 🇺🇸
Ruane Clinical Research Group, Los Angeles, California, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 808
- Registration Number
- NCT03053050
- Locations
- 🇧🇷
Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo, São Paulo, Brazil
🇺🇸Baptist Medical Center, Little Rock, Arkansas, United States
🇺🇸Southern California Liver Centers, Coronado, California, United States
Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)
- Conditions
- Interventions
- First Posted Date
- 2017-02-08
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 78
- Registration Number
- NCT03046056
- Locations
- 🇺🇸
Gastro One, Germantown, Tennessee, United States
🇦🇹Medical University of Innsbruck, Department of Internal Medicine I, Innsbruck, Austria
🇺🇸University of Miami Crohn's and Colitis Center, Miami, Florida, United States
Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 95
- Registration Number
- NCT03036839
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Henry Ford Health System, Detroit, Michigan, United States
🇺🇸James J. Peters VA Hospital, Bronx, New York, United States
Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease
- First Posted Date
- 2017-01-30
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 59
- Registration Number
- NCT03036852
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
🇳🇿Auckland City Hospital, Grafton, Auckland, New Zealand
🇬🇧Chelsea and Westminster Hospital, London, United Kingdom
Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 216
- Registration Number
- NCT03022981
- Locations
- 🇺🇸
Johns Hopkins University (JHU) - The Johns Hopkins Hospital (JHH), Baltimore, Maryland, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 102
- Registration Number
- NCT02996682
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis
- First Posted Date
- 2016-12-15
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT02994056
- Locations
- 🇺🇸
Northwestern Memorial Hospital; Clinical Research Unit, Chicago, Illinois, United States
🇺🇸Tampa General Medical Group, Tampa, Florida, United States
🇺🇸Digestive Disease Associates, PA, Catonsville, Maryland, United States
GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-12-06
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 14
- Registration Number
- NCT02983604
- Locations
- 🇺🇸
Stanford Women's Cancer Center, Stanford, California, United States
🇺🇸Allina Health, Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States
🇺🇸Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane, Washington, United States